Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.
The settlement covers patent infringement cases over coronary stent technology in the U.S., the U.K., Germany and Holland, according to an OrbusNeich press release.
"The agreement, which includes a one-time payment from Boston Scientific to OrbusNeich, settles all stent-related disputes between the companies and does not include future financial obligations," according to the release.
A German court in April granted an injunction against importing into that country drug-eluting stents including versions of Boston Scientific’s Promus Element, Promus Element Plus, Omega, Taxus Element, Synergy and Promus Premier devices. Earlier this month the Dusseldorf Regional Court issued a 2nd injunction after Orbus alleged that BSX was trying an end-run around t he injunction by using a British subsidiary.
OrbusNeich accused Boston Scientific of attempting an end-run around the ban by using a pair of British subsidiaries "to intentionally circumvent a prior order of the court banning sales of the same stent systems in Germany by other entities in the Boston Scientific corporate group," OrbusNeich said at the time. The Ft. Lauderdale-based medical device company later claimed that Natick, Mass.-based Boston Scientific sought to conceal the presence of the banned stents in a Ratlingen, Germany, facility. Boston Scientific denied the accusation in an email to MassDevice.com in May.
